BAKER BROTHERS INVESTMENTS
BAKER BROS. ADVISORS LP Legal Name
Adviser information for BAKER BROTHERS INVESTMENTS last updated from Form ADV on March 28th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
| Type of Organization | Limited Partnership |
|---|---|
| Fiscal Year End | DECEMBER |
| Legal Location | Delaware, United States |
Employees
| Total Number of Employees | 52 |
|---|---|
| Investment Advisory/Research | 18 |
| Registered Broker-Dealer Representatives | 0 |
| Registered State Investment Advisers | 0 |
| Licensed Agents of an Insurance Company | 0 |
| No. of Firms/People that Solicit Clients | 0 |
RAUM
| Provides Management of Securities Portfolios | Yes |
|---|
| Type | Accounts | RAUM |
|---|---|---|
| Discretionary | 2 | $22.0B |
| Non-Discretionary | 0 | $0 |
| Total | 2 | $22.0B |
Clients
| Type | Number | RAUM |
|---|---|---|
| Individuals | 0 | $0 |
| HNW Individuals | 0 | $0 |
| Banking or thrift institutions | 0 | $0 |
| Investment companies | 0 | $0 |
| Business development companies | 0 | $0 |
| Pooled investment vehicles | 2 | $22.0B |
| Pension and profit sharing plans | 0 | $0 |
| Charitable organizations | 0 | $0 |
| State or municipal gov entities | 0 | $0 |
| Other investment advisers | 0 | $0 |
| Insurance companies | 0 | $0 |
| Sovereign wealth funds and foreign official institutions | 0 | $0 |
| Corporations or other businesses | 0 | $0 |
| Other | 0 | $0 |
| Type | Number |
|---|---|
| No. of Non-RAUM Clients | 0 |
| No. of Non-U.S. Clients | 0 |
Services
| Advisory Services | Portfolio management for pooled investment vehiclesPortfolio management for businesses or institutional clients |
|---|---|
| Compensation | % of AUMPerformance-based fees |
Principal Office
860 WASHINGTON STREET, 3RD FLOORNEW YORK
NY
United States
Monday - Friday, 9AM - 6PM
Tel: 212-339-5600, Fax: 212-339-5688
Chief Compliance Officer
SCOTT L. LESSING
PRESIDENT
860 WASHINGTON STREET, 3RD FLOOR
NEW YORK
NY
United States
Tel:
212-339-5600
Fax:
212-339-5688
B***********@****************M
(Full email address available in API data)
Industry Affiliates
| BAKER BIOTECH CAPITAL, L.P. | Sponsor, GP, manager of pooled investment vehicles |
| BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. | Sponsor, GP, manager of pooled investment vehicles |
Private Funds
| Name | Type | Assets $USD | Min Investment $USD | No. Owners |
|---|---|---|---|---|
| 667, L.P. | Hedge Fund | $1,516.6M | $40.0M | 9 |
| BAKER BROTHERS LIFE SCIENCES, L.P. | Hedge Fund | $20,459.6M | $40.0M | 330 |
Control Persons
| Name | Type | Entity | Title | Since | Ownership |
|---|---|---|---|---|---|
| TOOHEY, ALEXANDRA, ANN | Individual | – | CHIEF FINANCIAL OFFICER | 01/2014 | < 5% |
| BAKER, JULIAN, CHARLES | Individual | – | LIMITED PARTNER | 01/2000 | 25-50% |
| BAKER, FELIX, JAMES | Individual | – | LIMITED PARTNER | 01/2000 | 25-50% |
| LESSING, SCOTT, LAWRENCE | Individual | – | PRESIDENT, CHIEF COMPLIANCE OFFICER | 02/2011 | < 5% |
| BAKER, JULIAN, CHARLES | Individual | BAKER BROS. ADVISORS (GP), LLC | MANAGING MEMBER | 01/2000 | 50-75% |
| BAKER, FELIX, JAMES | Individual | BAKER BROS. ADVISORS (GP), LLC | MANAGING MEMBER | 01/2000 | 50-75% |
| BAKER BROS. ADVISORS (GP), LLC | Domestic Entity | – | GENERAL PARTNER | 01/2000 | < 5% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
| Name | Class | Value $USD | # Shares | Private Fund |
|---|---|---|---|---|
| 2seventy bio, Inc. | COMMON STOCK | 10M | 2M | – |
| AbCellera Biologics Inc. | COM | 81M | 28M | – |
| ACADIA Pharmaceuticals Inc. | COM | 697M | 43M | – |
| Achilles Therapeutics plc | SPONSORED ADS | 904K | 1M | – |
| Acrivon Therapeutics, Inc. | COMMON STOCK | 307K | 53K | – |
| Adaptimmune Therapeutics plc | SPONSORED ADR | 2M | 2M | – |
| Aerovate Therapeutics, Inc. | COM | 1M | 629K | – |
| Akero Therapeutics, Inc. | COM | 26M | 1M | – |
| Alector, Inc. | COM | 4M | 927K | – |
| Aligos Therapeutics, Inc. | COM | 727K | 2M | – |
| Alkermes plc | SHS | 101M | 4M | – |
| Alumis Inc. | COM | 21M | 2M | – |
| Arcturus Therapeutics Holdings Inc. | COM | 4M | 151K | – |
| argenx SE | SPONSORED ADR | 48M | 112K | – |
| Athira Pharma, Inc. | COM | 8M | 3M | – |
| BeiGene, Ltd. | SPONSORED ADR | 2B | 11M | – |
| Bicycle Therapeutics plc | SPONSORED ADS | 190M | 9M | – |
| BioCryst Pharmaceuticals, Inc. | COM | 468K | 76K | – |
| Biomea Fusion, Inc. | COM | 9M | 2M | – |
| Celcuity Inc. | COM | 31M | 2M | – |
| Celldex Therapeutics, Inc. | COM | 9M | 248K | – |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 5M | 549K | – |
| Century Therapeutics, Inc. | COM | 2M | 797K | – |
| Cerevel Therapeutics Holdings, Inc. | COM | 28M | 684K | – |
| Cerus Corporation | COM | 34M | 19M | – |
| Compass Therapeutics, Inc. | COM | 2M | 2M | – |
| Contineum Therapeutics, Inc. | CL A | 6M | 313K | – |
| Crinetics Pharmaceuticals, Inc. | COM | 5M | 104K | – |
| CRISPR Therapeutics AG | NAMEN AKT | 5M | 100K | – |
| DBV Technologies S.A. | SPONSORED ADR | 6M | 7M | – |
| Denali Therapeutics Inc. | COM | 87M | 4M | – |
| Design Therapeutics, Inc. | COM | 6M | 2M | – |
| Dyne Therapeutics, Inc. | COM | 24M | 672K | – |
| Edgewise Therapeutics, Inc. | COM | 105M | 6M | – |
| Enliven Therapeutics, Inc. | COM | 3M | 115K | – |
| Entrada Therapeutics, Inc. | COM | 69M | 5M | – |
| Fate Therapeutics, Inc. | COM | 10M | 3M | – |
| Foghorn Therapeutics Inc. | COM | 259K | 45K | – |
| Generation Bio Co. | COM | 3M | 1M | – |
| HOOKIPA Pharma Inc. | COM | 5M | 8M | – |
| IDEAYA Biosciences, Inc. | COM | 37M | 1M | – |
| IGM Biosciences, Inc. | COM | 28M | 4M | – |
| Immatics N.V. | SHS | 75M | 6M | – |
| Immunocore Holdings plc | ADS | 51M | 2M | – |
| Immunovant, Inc. | COM | 12M | 465K | – |
| Incyte Corporation | COM | 2B | 31M | – |
| Insmed Incorporated | COM PAR $.01 | 240M | 4M | – |
| KALA BIO, Inc. | COM | 6M | 891K | – |
| Kiniksa Pharmaceuticals International, plc | ORD SHS CL A | 53M | 3M | – |
| Kodiak Sciences Inc. | COM | 41M | 17M | – |
| Krystal Biotech, Inc. | COM | 31M | 170K | – |
| Kymera Therapeutics, Inc. | COM | 179M | 6M | – |
| Leap Therapeutics, Inc. | COM | 2M | 1M | – |
| Madrigal Pharmaceuticals, Inc. | COM | 553M | 2M | – |
| Mersana Therapeutics, Inc. | COM | 2M | 1M | – |
| Merus N.V. | COM | 18M | 300K | – |
| Mirum Pharmaceuticals, Inc. | COM | 7M | 190K | – |
| Monte Rosa Therapeutics, Inc. | COM | 18M | 5M | – |
| Neumora Therapeutics, Inc. | COM | 10M | 1M | – |
| Neurogene Inc. | COM | 17M | 456K | – |
| NewAmsterdam Pharma Company N.V. | ORDINARY SHARES | 2M | 97K | – |
| Nurix Therapeutics, Inc. | COM | 81M | 4M | – |
| Opthea Limited | SPONSORED ADS | 4M | 2M | – |
| Pfizer Inc. | COM | 979K | 35K | – |
| PMV Pharmaceuticals, Inc. | COM | 522K | 322K | – |
| Praxis Precision Medicines, Inc. | COM | 5M | 132K | – |
| Prelude Therapeutics Inc. | COM | 39M | 10M | – |
| Prime Medicine, Inc. | COM | 5M | 1M | – |
| Protara Therapeutics, Inc. | COM STK | 1M | 537K | – |
| Relay Therapeutics, Inc. | COM | 8M | 1M | – |
| Replimune Group, Inc. | COM | 90M | 10M | – |
| Revolution Medicines, Inc. | COM | 294M | 8M | – |
| Rhythm Pharmaceuticals, Inc. | COM | 263M | 6M | – |
| Roivant Sciences Ltd. | SHS | 30M | 3M | – |
| Sage Therapeutics, Inc. | COM | 2M | 171K | – |
| Sagimet Biosciences Inc. | COM SER A | 5M | 1M | – |
| Sana Biotechnology, Inc. | COM | 13M | 2M | – |
| Sera Prognostics, Inc. | CLASS A COM | 32M | 5M | – |
| Skye Bioscience, Inc. | COM | 4M | 500K | – |
| Stoke Therapeutics, Inc. | COM | 59M | 4M | – |
| Summit Therapeutics Inc. | COM | 181M | 23M | – |
| Surrozen, Inc. | W EXP 8/11/2026 | 14K | 833K | – |
| Talis Biomedical Corporation | COM | 4M | 508K | – |
| Tango Therapeutics, Inc. | COM | 6M | 750K | – |
| Taysha Gene Therapies, Inc. | COM SHS | 9M | 4M | – |
| TScan Therapeutics, Inc. | COM | 16M | 3M | – |
| Tyra Biosciences, Inc. | COM | 170K | 11K | – |
| Ultragenyx Pharmaceutical Inc. | COM | 60M | 1M | – |
| Vaxcyte, Inc. | COM | 4M | 49K | – |
| Verve Therapeutics, Inc. | COM | 8M | 2M | – |
| vTv Therapeutics, Inc. | CL A | 2M | 97K | – |
| Xencor, Inc. | COM | 10M | 545K | – |
| Xenon Pharmaceuticals Inc. | COM | 39M | 994K | – |
| Insmed Incorporated | Note 0.75% 6/1/2028 | 90M | – | – |
| Insmed Incorporated | Note 1.75% 1/15/2025 | 56M | – | – |